GILD Jun 2024 58.000 call
| Previous Close | 6.80 |
| Open | N/A |
| Bid | 4.25 |
| Ask | 5.70 |
| Strike | 58.00 |
| Expire Date | 2024-06-07 |
| Day's Range | 6.80 - 6.80 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 3 |
ZacksGilead (GILD), RCUS Announce Data From Colorectal Cancer Study
Gilead (GILD) and partner Arcus Biosciences (RCUS) present data from metastatic colorectal cancer and gastrointestinal cancer study.
ZacksTop Stock Reports for NextEra Energy, BP & Gilead Sciences
Today's Research Daily features new research reports on 16 major stocks, including NextEra Energy, Inc. (NEE), BP p.l.c. (BP) and Gilead Sciences, Inc. (GILD), as well as two micro-cap stocks Hamilton Beach Brands Holding Company (HBB) and FONAR Corporation (FONR).
Business WireKite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
SANTA MONICA, Calif., June 03, 2024--Kite, a Gilead Company (Nasdaq: GILD), today announced updated, four-year overall survival (OS) data from the pivotal ZUMA-3 study evaluating the CAR T-cell therapy Tecartus® (brexucabtagene autoleucel) in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). The findings showed a median OS of 25.6 months and a four-year OS rate of 40% (95% CI, 28-52) in all treated patients with a safety profile consistent with that obse
